References
- Alisa A, Ives A, Pathan AA, et al (2005). Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res, 11, 6686-94. https://doi.org/10.1158/1078-0432.CCR-05-0382
- Alving CR, Peachman KK, Rao M, et al (2012). Adjuvants for human vaccines. Curr Opin Immunol, 24, 310-5. https://doi.org/10.1016/j.coi.2012.03.008
- Arihara F, Mizukoshi E, Kitahara M, et al (2013). Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother, 62, 1421-30. https://doi.org/10.1007/s00262-013-1447-1
- Arruebo M, Fernandez-Pacheco R, Ibarra MR, et al (2007). Magnetic nanoparticles for drug delivery. Nano Today, 2, 22-32.
- Belardelli F, Ferrantini M, Proietti E, et al (2002). Interferonalpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 13, 119-34. https://doi.org/10.1016/S1359-6101(01)00022-3
- Bode C, Zhao G, Steinhagen F, et al (2011). CpG DNA as a vaccine adjuvant. Expert Rev Vaccines, 10, 499-511. https://doi.org/10.1586/erv.10.174
- Brannon-Peppas L, Blanchette JO (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56, 1649-59. https://doi.org/10.1016/j.addr.2004.02.014
- Chen KJ, Lin SZ, Zhou L, et al (2011). Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One, 6, e24671. https://doi.org/10.1371/journal.pone.0024671
- Chen W, Zheng R, Zeng H, et al (2014). Trend analysis of the changes of male/female, urban/rural incidences and average age of cancer patients in China 1989-2008. Chin J Oncol, 36, 796-800.
- Chen Z, Shen S, Peng B, et al (2009). Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model. Int J Hyperthermia, 25, 374-82. https://doi.org/10.1080/02656730902976807
- Cheng M, Chen Y, Xiao W, et al (2013). NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol, 10, 230-52. https://doi.org/10.1038/cmi.2013.10
- Cheng Y, Zhang G, Li G (2013). Targeting MAPK pathway in melanoma therapy. Cancer Metastasis Rev, 32, 567-84. https://doi.org/10.1007/s10555-013-9433-9
- Crispe IN, Giannandrea M, Klein I, et al (2006). Cellular and molecular mechanisms of liver tolerance. Immunol Rev, 213, 101-18. https://doi.org/10.1111/j.1600-065X.2006.00435.x
- Ferlay J, Shin H, Bray F, et al (). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide; IARC Cancer Base No. 10; International Agency for Research on Cancer: Lyon, France, 2010; Volume 2010, p. 29.
- Gao Q, Qiu SJ, Fan J, et al (2007). Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol, 25, 2586-2593. https://doi.org/10.1200/JCO.2006.09.4565
- Hoechst B, Voigtlaender T, Ormandy L, et al (2009). Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 50, 799-807. https://doi.org/10.1002/hep.23054
- Ilkovitch D, Lopez DM (2009). The liver is a site for tumorinduced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res, 69, 5514-21. https://doi.org/10.1158/0008-5472.CAN-08-4625
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Kalyanaraman B, Joseph J, Kalivendi S, et al (2002). Doxorubicininduced apoptosis: implications in cardiotoxicity. Mol Cell Biochem, 234-235, 119-124. https://doi.org/10.1023/A:1015976430790
- Komorizono Y, Kohara K, Oketani M, et al (2003). Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci, 48, 877-81. https://doi.org/10.1023/A:1023035109665
- Lin SM, Lin CJ, Hsu CW, et al (2004). Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer, 100, 376-82. https://doi.org/10.1002/cncr.20004
- Liu L (2014). The global significance of China's cancer burden and control effort. Ann Transl Med, 2014, 2.
- National Bureau of Statistics of China (2011). China Population and Employment Statistics Yearbook, China Statistics Press: Beijing, China, 2012.
- Naumov GN, Townson JL, MacDonald IC, et al (2003). Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat, 82, 199-206. https://doi.org/10.1023/B:BREA.0000004377.12288.3c
- Obi S, Yoshida H, Toune R, et al (2006). Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer, 106, 1990-7. https://doi.org/10.1002/cncr.21832
- Ormandy LA, Hillemann T, Wedemeyer H, et al (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 65, 2457-64. https://doi.org/10.1158/0008-5472.CAN-04-3232
- Ozols RF, Herbst RS, Colson YL, et al (2006). Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American society of clinical oncology. Jpn J Clin Oncol, 25, 146-62. https://doi.org/10.1200/JCO.2006.09.7030
- Patt YZ, Hassan MM, Lozano RD, et al (2003). Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol, 21, 421-7. https://doi.org/10.1200/JCO.2003.10.103
- Peng XH, Qian X, Mao H, et al (2008). Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine, 3, 311-21.
- Rosenberg SA, Yang JC, Restifo NP, et al (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med, 10, 909-15. https://doi.org/10.1038/nm1100
- Rosenberg SA (2001). Progress in human tumour immunology and immuno-therapy. Nature, 411, 380-4. https://doi.org/10.1038/35077246
- Rosenberg SA, Yang JC, White DE, et al (1998). Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg, 228, 307-19. https://doi.org/10.1097/00000658-199809000-00004
- Rougier P, Mitry E, Barbare JC, et al (2007). Hepatocellular carcinoma (HCC): an update. Semin Oncol, 34, S12-20. https://doi.org/10.1053/j.seminoncol.2007.01.007
- Schuster M, Nechansky A, Kircheis R (2006) . Cancer immunotherapy. Biotechnol J, 1, 138-47. https://doi.org/10.1002/biot.200500044
- Serda RE (2013) . Particle platforms for cancer immunotherapy. Int J Nanomedicine, 8, 1683-96.
- Shurin MR, Naiditch H, Gutkin DW, et al (2012). ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. Curr Med Chem, 19, 1792-803. https://doi.org/10.2174/092986712800099785
- Singh RK, Gutman M, Bucana CD, et al (1995). Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA, 92, 4562-6. https://doi.org/10.1073/pnas.92.10.4562
- Sun HC, Tang ZY, Wang L, et al (2006). Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol, 132, 458-65. https://doi.org/10.1007/s00432-006-0091-y
- Talmadge JE (1998). Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev, 33, 241-52. https://doi.org/10.1016/S0169-409X(98)00032-5
- Vadrot N, Legrand A, Nello E, et al (2006). Inducible nitric oxide synthase (iNOS) activity could be responsible for resistance or sensitivity to IFN-gamma-induced apoptosis in several human hepatoma cell lines. J Interferon Cytokine Res, 26, 901-13. https://doi.org/10.1089/jir.2006.26.901
- WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online: http://globocan.iarc.fr (accessed on 17 May 2015).
Cited by
- Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
- A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
- Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2027
- Electrospun poly(l-lactide)/zein nanofiber mats loaded with Rana chensinensis skin peptides for wound dressing vol.27, pp.9, 2016, https://doi.org/10.1007/s10856-016-5749-7
- The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5055
- Correlation between secreted protein acidic and rich in cysteine protein expression and the prognosis of postoperative patients exhibiting esophageal squamous cell carcinoma vol.16, pp.3, 2017, https://doi.org/10.3892/mmr.2017.6959
- /RCSPs core–shell structure nanofibers by electrospinning for wound dressings vol.8, pp.28, 2018, https://doi.org/10.1039/C8RA00784E